Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Mastic and Reduced Interleukin-10 Levels

Doses used in studies

g/day: 2.1 (median 2.1, IQR 2.1–2.1) — 1 study

Time to effect

Median: 6 months · IQR 6 months–6 months · Range 6 months–6 months — Reported in 1 of 1 study

1 of 1 paper

Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD.
- 2021-05-07
- RCT · n = 98
- Frontiers in immunology 12
- - Stavroula Kanoni
  - Satish Kumar
  - Charalampia Amerikanou
  - Mary Jo Kurth
  - Maria G Stathopoulou
  - Stephane Bourgeois
  - Christine Masson
  - Aimo Kannt
  - Lucia Cesarini
  - Maria-Spyridoula Kontoe
  - Maja Milanović
  - Francisco J Roig
  - Mirjana Beribaka
  - Jonica Campolo
  - Nuria Jiménez-Hernández
  - Nataša Milošević
  - Carlos Llorens
  - Ilias Smyrnioudis
  - M Pilar Francino
  - Nataša Milić
  - Andriana C Kaliora
  - Maria Giovanna Trivella
  - Mark W Ruddock
  - Milica Medić-Stojanoska
  - Amalia Gastaldelli
  - John Lamont
  - Panos Deloukas
  - George V Dedoussis
  - Sophie Visvikis-Siest
- PubMed: 34025683
- DOI: 10.3389/fimmu.2021.683028
5 Insights on
- Reduced Interleukin-10 Levels
- High evidence
- Clinical
the granzyme B gene (GZMB) associated with IL-10 levels
Effect
Neutral
Effect size
Small
Significant
No
Dose
2.1 g/day